Today: Today, Delta Lloyd NV Continues to Hold Position in Regeneron Pharmaceuticals Inc. (REGN)

Today, Delta Lloyd NV Continues to Hold Position in Regeneron Pharmaceuticals Inc. (REGN)

Delta Lloyd NV maintained its stake in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) during the third quarter, Holdings Channel reports. The institutional investor owned 5,913 shares of the biopharmaceutical company’s stock at the end of the third quarter. Delta Lloyd NV’s holdings in Regeneron Pharmaceuticals were worth $2,377,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in REGN. Winslow Capital Management LLC bought a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $291,760,000. FMR LLC increased its position in Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock valued at $3,288,642,000 after buying an additional 795,283 shares during the period. Capital World Investors increased its position in Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock valued at $2,558,678,000 after buying an additional 312,008 shares during the period. Emerald Acquisition Ltd. bought a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $87,319,000. Finally, BlackRock Investment Management LLC increased its position in Regeneron Pharmaceuticals by 136.0% in the second quarter. BlackRock Investment Management LLC now owns 403,418 shares of the biopharmaceutical company’s stock valued at $140,886,000 after buying an additional 232,471 shares during the period. Institutional investors own 68.45% of the company’s stock.

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 1.06% during trading on Friday, reaching $398.16. The company’s stock had a trading volume of 279,941 shares. Regeneron Pharmaceuticals Inc. has a 12 month low of $325.35 and a 12 month high of $566.52. The stock’s 50 day moving average price is $381.56 and its 200-day moving average price is $389.13. The firm has a market cap of $41.74 billion, a PE ratio of 58.09 and a beta of 1.79.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.73 by $0.40. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The business’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.47 EPS. Equities analysts predict that Regeneron Pharmaceuticals Inc. will post $11.73 EPS for the current year.

Several equities analysts recently commented on REGN shares. Goldman Sachs Group Inc. restated a “buy” rating and set a $521.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 27th. Roth Capital restated a “buy” rating and set a $520.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 12th. Jefferies Group restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 17th. Leerink Swann reaffirmed a “buy” rating and set a $530.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 21st. Finally, Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price target for the company in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $468.87.

In other news, Director Arthur F. Ryan sold 2,000 shares of the stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total transaction of $858,680.00. Following the transaction, the director now owns 36,500 shares of the company’s stock, valued at approximately $15,670,910. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $450.00, for a total transaction of $956,250.00. Following the transaction, the director now directly owns 15,125 shares in the company, valued at approximately $6,806,250. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Related posts

Leave a Comment